treatment options are limited and there are currently no approved medications
For the more than 17 million people worldwide living with binge eating disorder—a condition that leaves them without a single approved medication—a large UCL-led review of 25 clinical trials offers a cautious but meaningful signal: drugs already prescribed for obesity may also quiet the compulsive, loss-of-control eating that defines the disorder. The findings, drawn from over 8,000 participants across four continents, suggest that GLP-1 receptor agonists like semaglutide and tirzepatide reach not only the body's hunger mechanisms but perhaps the brain's relationship with reward and restraint. Yet the researchers are careful to hold hope and humility in equal measure, noting that most evidence comes from industry-funded trials in people without a formal diagnosis—a reminder that a promising signal is not yet a proven path.
- Seventeen million people live with binge eating disorder and currently have no approved pharmaceutical treatment, leaving many to navigate a condition that can be deeply impairing with little more than uneven access to therapy.
- A UCL meta-analysis of 25 randomized controlled trials found that GLP-1 drugs—already reshaping how medicine treats obesity—also reduced binge episodes, loss-of-control eating, and emotionally driven eating across 8,069 participants.
- A critical ambiguity shadows the findings: participants also showed increased dietary restraint, and researchers cannot yet determine whether that restraint is healthy self-regulation or the beginning of a more harmful restrictive pattern.
- The evidence base carries serious structural weaknesses—most trials were industry-funded, carried high bias risk, and enrolled people seeking weight loss rather than those with a confirmed binge eating disorder diagnosis.
- Researchers and their lived-experience advisors stress that medication alone is insufficient, calling for independent large-scale trials, integrated psychological support, and systemic efforts to reduce the stigma and financial barriers that keep treatment out of reach.
Researchers at University College London have completed the largest systematic review to date examining whether GLP-1 receptor agonists—drugs like semaglutide and tirzepatide, widely prescribed for obesity—might also help treat binge eating disorder. Published in eClinicalMedicine, the review synthesized 25 randomized controlled trials from 12 countries, drawing on data from 8,069 participants. The findings suggest these medications can reduce the frequency of binge episodes, loss-of-control eating, and eating driven by emotional distress—meaningful results for a condition that currently has no approved pharmaceutical treatments and affects more than 17 million people worldwide.
The drugs work by targeting the appetite-regulating hormone GLP-1, suppressing hunger through effects on the central nervous system, slowing gastric emptying, and potentially reshaping how the brain processes reward and impulse. Lead author Dr. Ilaria Costantini noted the significance of the findings given how few options currently exist: psychological therapies are available but access is uneven, and many patients must pay privately for care. The possibility that existing weight-loss medications could address binge eating symptoms opens a new treatment avenue.
Yet the study surfaces an important unresolved question. Participants also reported increased dietary restraint, and first author Izzy Emptage cautioned that the team cannot yet determine whether this reflects healthy self-regulation or a more dysfunctional pattern—a distinction that matters deeply in the context of eating disorders, where rigid restriction can itself become harmful.
The researchers are clear that medication alone will not be enough. Input from a lived experience panel underscored that lasting recovery requires medication alongside psychological support and broader efforts to reduce weight stigma. Emptage also noted that many people with binge eating disorder cannot access these drugs through public healthcare, adding financial hardship to an already difficult condition.
Significant limitations temper the findings. Most trials carried a high risk of bias and were funded by pharmaceutical companies, and crucially, the vast majority of participants did not have a clinical diagnosis of binge eating disorder—they were primarily people seeking weight loss. The researchers are calling for robust, independently funded trials with longer follow-up periods and confirmed diagnoses before these findings can be translated into clinical practice.
A team of researchers at University College London has completed the largest systematic review to date on whether weight-loss medications might help treat binge eating disorder—a condition that affects more than 17 million people worldwide and currently has no approved pharmaceutical treatments. The findings, published in eClinicalMedicine, suggest that GLP-1 receptor agonists—drugs like semaglutide and tirzepatide that are widely prescribed for obesity—can reduce the frequency of binge episodes, episodes of eating without a sense of control, and eating driven by emotional distress.
The review synthesized evidence from 25 randomized controlled trials conducted across 12 countries on four continents, drawing on data from 8,069 participants. These medications work by targeting the appetite-regulating hormone GLP-1, suppressing hunger through effects on the central nervous system and insulin secretion, delaying how quickly the stomach empties, and potentially altering how the brain processes reward and impulse control. The researchers found that beyond weight reduction, participants experienced measurable improvements in the core behavioral symptoms of binge eating disorder—a condition characterized by regular episodes of consuming large amounts of food while feeling a loss of control.
Dr. Ilaria Costantini, the lead author from UCL's psychiatry department, emphasized the significance of the finding given the current treatment landscape. "Binge eating disorder is common and highly impairing," she said, "but treatment options are limited and there are currently no approved medications." The condition leaves people searching for help with few options: psychological therapies exist, but access is uneven, and many patients must pay out of pocket for private treatment. The possibility that existing weight-loss drugs might address binge eating symptoms opens a new avenue for intervention.
The researchers also observed that participants reported increased dietary restraint—a measure of how intentionally people limit their eating. But this finding comes with an important caveat. Izzy Emptage, a Ph.D. candidate and first author on the study, cautioned that the research team cannot yet determine whether this restraint represents healthy self-regulation or a more problematic pattern. "We cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating," Emptage said. The concern is real: in eating disorders, rigid restriction can itself become pathological, and future research will need to clarify whether these medications might inadvertently encourage harmful eating patterns like meal skipping.
The researchers emphasize that medication alone is unlikely to be sufficient. Costantini noted that the study benefited from input from a lived experience panel—people with direct knowledge of binge eating disorder—who stressed that sustainable recovery depends on a combination of medication, psychological support, and broader social and community efforts to reduce weight bias and stigma. Emptage added that many people with binge eating disorder cannot access these drugs through public healthcare systems, forcing them to seek private treatment at considerable personal expense. The researchers hope their findings will spur investment in larger, higher-quality studies.
But significant limitations remain. Most of the trials included in the review carried a high risk of bias and were funded by pharmaceutical companies. Crucially, the vast majority of study participants did not have a clinical diagnosis of binge eating disorder—they were primarily people seeking weight loss. This gap means the evidence for how these drugs work specifically in people with binge eating disorder remains uncertain. The researchers are calling for robust, independently funded trials with long follow-up periods that include people with confirmed binge eating disorder diagnoses. Only then will it be clear whether the short-term improvements observed in these studies translate into lasting, meaningful change in people's lives.
Notable Quotes
Binge eating disorder is common and highly impairing, but treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition.— Dr. Ilaria Costantini, UCL Psychiatry
We cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating.— Izzy Emptage, UCL Psychiatry
The Hearth Conversation Another angle on the story
So these are weight-loss drugs that seem to help with binge eating. But binge eating and obesity aren't the same thing, are they?
No, they're distinct. Obesity is about body weight. Binge eating disorder is a psychiatric condition—it's about losing control during eating episodes. Some people with binge eating disorder are overweight, some aren't. The drugs appear to address the behavioral symptom—the loss of control—not just the weight.
How do they do that? What's the mechanism?
They target an appetite hormone called GLP-1, which affects hunger signals in the brain. But they also seem to influence how the brain processes reward and impulse control. So it's not just about feeling less hungry—it's about the brain's ability to regulate the urge to binge.
The article mentions a concern about dietary restraint becoming unhealthy. Can you explain that worry?
In eating disorders, sometimes the "solution" becomes another problem. If someone swings from binge eating to rigid restriction—skipping meals, obsessive calorie counting—that's not recovery, that's a different disorder. The researchers don't yet know if these drugs might push some people in that direction.
Why does it matter that most trial participants didn't have a clinical diagnosis of binge eating disorder?
Because the drugs were tested mainly on people trying to lose weight, not on people whose primary problem is loss-of-control eating. Those are different populations with different brain patterns. You can't be sure the benefits will transfer.
So what happens next?
Larger, independent studies with people who actually have binge eating disorder diagnoses. And longer follow-up to see if the improvements last. Right now we have promising signals, but not proof.